These observations of reduced binding in vitro suggest that the replacement of arginine with glutamine in BD probands may diminish RGS12’s binding strength to its in vivo targets, including the candidate interactors CXCR2, MEK2, and SAPAP3. This evidence concerns the gene MAP2K2 and Behcet disease.